Exelixis’ (EXEL) lead drug, Cabometyx, a tyrosine kinase inhibitor (TKI), maintains a dominant position for the treatment of renal cell carcinoma (RCC) in both the frontline immuno-oncology (IO) +TKI ...
Exelixis, Inc. focuses on oncology medicines, primarily deriving revenue from Cabometyx, with zanzalintinib as its next-generation TKI candidate. Cabometyx, a multiple tyrosine kinase inhibitor, ...
Cabometyx is now approved for advanced pancreatic and extra-pancreatic NETs, offering a new treatment option for these patients. The phase 3 CABINET trial showed Cabometyx significantly improved ...
It's not the most prominent company in its industry, but it is definitely worth a second look.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results